Physician profile
Michael D Stubblefield
NPI 1396716338
$52,732.52
in general payments reported to CMS, 2019-2025
19 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $7,470 · 2022: $1,939 · 2023: $719 · 2024: $3,799 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $4,610 · Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,200.00 |
| Travel and Lodging | $4,609.99 |
| Food and Beverage | $1,186.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $51,772.83 | 2019-2025 | Flexitouch Plus, Nimbl, Flexitouch Plus |
| Allergan, INC. | $536.59 | 2019-2020 | |
| Abbvie INC. | $97.30 | 2022-2024 | Botox |
| Merz Pharmaceuticals, LLC | $38.69 | 2024-2025 | Xeomin |
| Merz North America, INC. | $34.95 | 2019 | |
| Azurity Pharmaceuticals, INC. | $30.81 | 2023-2024 | Horizant, Horizant |
| Pacira Therapeutics, INC. | $26.99 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.62 | 2019 | |
| Abbott Laboratories | $20.36 | 2019 | |
| Axsome Therapeutics, INC. | $17.95 | 2023 | Sunosi |
| Coloplast Corp | $16.70 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.27 | 2023 | Nuedexta |
| Lundbeck LLC | $15.52 | 2024 | Vyepti |
| Pfizer INC. | $14.93 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.14 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $14.05 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.64 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.27 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stubblefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.